BSE · 540204
EIKO Lifesciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹1 Cr — a 7.48% net margin, versus 7.04% the period before.
Shareholding
As of 2026-06-30
- Promoter39.91%
- Public60.09%
3,019 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.44× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #121 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Solar Industries India Ltd. | ₹2,02,833 Cr | 101.85 | 32.31 | 26.72% | 17.54% |
| Pidilite Industries Ltd. | ₹1,58,779 Cr | 59.95 | 14.66 | 22.61% | 17.2% |
| SRF Ltd. | ₹73,899 Cr | 32.98 | 5.26 | 13.07% | 13.01% |
| Linde India Limited | ₹52,791 Cr | 96.61 | 12.37 | 12.87% | 20.59% |
| Gujarat Fluorochemicals Ltd. | ₹52,507 Cr | 85.01 | 6.72 | 7.13% | 11.41% |
| Navin Fluorine International Ltd. | ₹44,315 Cr | 55.72 | 11.15 | 16.69% | 21.73% |
| Godrej Industries Ltd. | ₹37,215 Cr | 30.42 | 3.33 | 11.1% | 5.06% |
| Himadri Speciality Chem Limited | ₹33,098 Cr | 41.41 | 7.03 | 15.96% | 16.07% |
| Deepak Nitrite Ltd. | ₹21,819 Cr | 27.54 | 3.74 | 9.43% | 9.13% |
| Aether Industries Limited | ₹21,697 Cr | 90.41 | 8.83 | 8.94% | 19.11% |
| EIKO Lifesciences Limited(this company) | ₹66 Cr | 13.58 | 1 | 6.54% | 8.34% |
AI analysis
AI-generated · google/gemini-2.5-flashEIKO Lifesciences Limited is listed with a market capitalization of Rs 70 Cr. The company reported revenue of Rs 38.38 Cr and a net profit of Rs 2.3186 Cr for the year ending March 2025. Earnings per share (EPS) stood at Rs 3.13 and the book value per share was Rs 47.94.
Positives
- +The company has a low debt-to-equity ratio of 0.05.
- +Promoter holding of 39.9055% as of March 2026 shows significant insider ownership.
- +No shares are pledged by the promoters, indicating financial stability.
Negatives
- −Promoter holding decreased from an unspecified percentage in March 2019 to 39.9055% by March 2026, though specific historical data is not available.
- −The company has not disclosed quarterly EPS figures for any period.
- −The company has a dividend yield of 0%, indicating no dividend payouts.
Financial Performance
For the fiscal year ending March 2025, EIKO Lifesciences Limited generated revenue of Rs 38.38 Cr. The company's net profit for the same period was Rs 2.3186 Cr. Quarterly revenue for March 2026 was Rs 18.34 Cr, with a net profit of Rs 1.3 Cr. Net profit for the quarter ending December 2025 was Rs 1.21 Cr on revenue of Rs 11.98 Cr.
Profitability & Returns
The company's profit margin was 8.54% as of March 2025. Return on equity (ROE) was 6.54% and return on capital employed (ROCE) was 10.1312%. The earnings per share (EPS) for the year ending March 2025 was Rs 3.13.
Balance Sheet
EIKO Lifesciences Limited has a debt-to-equity ratio of 0.05, indicating a low level of debt relative to equity. The book value per share is Rs 47.94.
Ownership & Pledges
As of March 2026, promoters held 39.9055% of the company's shares. Public shareholding was 60.0945%. There were no shares pledged by the promoters. The company has no DII or FII shareholding. The total number of shareholders was 2969.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.